Pulike Biological Engineering Inc
SSE:603566
Pulike Biological Engineering Inc
Total Equity
Pulike Biological Engineering Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pulike Biological Engineering Inc
SSE:603566
|
Total Equity
¥2.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Equity
¥28.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Equity
¥14B
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
18%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Equity
¥45.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Total Equity
¥3.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Equity
¥3.9B
|
CAGR 3-Years
127%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
Pulike Biological Engineering Inc
Glance View
Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
See Also
What is Pulike Biological Engineering Inc's Total Equity?
Total Equity
2.6B
CNY
Based on the financial report for Sep 30, 2024, Pulike Biological Engineering Inc's Total Equity amounts to 2.6B CNY.
What is Pulike Biological Engineering Inc's Total Equity growth rate?
Total Equity CAGR 5Y
10%
Over the last year, the Total Equity growth was -4%. The average annual Total Equity growth rates for Pulike Biological Engineering Inc have been 14% over the past three years , 10% over the past five years .
You don't have any saved screeners yet